MIRUM PHARMACEUTICALS INC (MIRM)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for MIRM
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| MIRM | Director | 62 | ["interim Chief Executive Officer of Respira Therapeutics, Inc.","Executive Vice President and Chief Commercial Officer at MyoKardia, Inc.","Executive Vice President and Chief Operating Officer at ChemoCentryx, Inc.","President of Actelion Pharmaceuticals US, Inc.","Regional Vice President, Australia Asia Pacific, of Actelion Pharmaceuticals Ltd.","President of Actelion Pharmaceuticals Canada Inc.","Vice President of Sales and Management Markets of Actelion Pharmaceuticals US, Inc.","serves on the boards of directors of Ascendis Pharma, Inc., Rein Therapeutics, Inc., and KalVista Pharmaceuticals, Inc.","B.S. in biology from the University of Oregon","M.B.A. from Saint Mary’s College"] | [] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| KALV | Director | 61 | [] | [] | 2025 |
Biography sourced from the proxy statement filing.
William Fairey has served as a member of the Board since 2021. Most recently, from July 2023 to January 2024, Mr. Fairey served as the interim Chief Executive Officer of Respira Therapeutics, Inc, a privately held pharmaceutical company. From January 2019 to November 2020, Mr. Fairey served as Executive Vice President and Chief Commercial Officer at MyoKardia, Inc., a biopharmaceutical company, where he built the commercial and portfolio strategy, established the company s European headquarters, and was structuring the expansion in Latin America and Asia when the company was acquired by Bristol-Myers Squibb. Prior to serving at MyoKardia, Mr. Fairey served as Executive Vice President and Chief Operating Officer at ChemoCentryx, Inc., a biopharmaceutical company, from March 2018 to January 2019, where, he was responsible for the sales, marketing, medical affairs and market access functions, including commercialization of late stages compounds. Prior to ChemoCentryx, Mr. Fairey served in a number of roles at Actelion Pharmaceuticals Ltd. and its subsidiaries including as President of Actelion Pharmaceuticals US, Inc., a pharmaceuticals and biotechnology company, from April 2013 to December 2017, Regional Vice President, Australia Asia Pacific, of Actelion Pharmaceuticals Ltd. from July 2008 to March 2013, President of Actelion Pharmaceuticals Canada Inc. from June 2003 to June 2008, and Vice President of Sales and Management Markets of Actelion Pharmaceuticals US, Inc. from January 2001 to June 2003. Mr. Fairey currently serves on the boards of directors of Ascendis Pharma, Inc., Rein Therapeutics, Inc. (formerly Aileron Therapeutics, Inc.) and KalVista Pharmaceuticals, Inc., each publicly held biopharmaceutical companies, as well as Respira Therapeutics, Inc., a privately held pharmaceutical company. Mr. Fairey received his B.S. in biology from the University of Oregon and an M.B.A. from Saint Mary s College. Skills and Qualifications specific to Mirum Pharmaceuticals, Inc.: The Board and Nominating Committee believe that Mr. Fairey s extensive experience building and operating global the commercial arms of several biotechnology businesses qualifies him to serve on the Board.